Clinical Trial Update: Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating aflibercept in patients with recurrent or metastatic thyroid cancer that did not respond to radioactive iodine; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-15